Treatment of Herpetic Lesions in the Mouth

Introduction to Treatment

The Centers for Disease Control and Prevention recommends initiating oral valacyclovir 1g twice daily for 5-10 days, or alternatively famciclovir 500mg twice daily or acyclovir 400mg three times daily for the same duration for oral herpetic lesions 1, 2

For mild herpetic gingivostomatitis, the American Academy of Pediatrics recommends acyclovir 400mg orally three times daily for 5-10 days, with a maximum dose based on 20mg/kg body weight, not exceeding 400mg/dose 2
For moderate to severe herpetic gingivostomatitis, the Centers for Disease Control and Prevention recommends initiating IV acyclovir 5-10mg/kg body weight every 8 hours, and transitioning to oral therapy once lesions begin to regress 1, 2

The American Academy of Dermatology recommends that treatment must begin within 24 hours of symptom onset or during the prodromal phase for maximum efficacy 3, 4
Peak viral titers occur in the first 24 hours, making early intervention essential, as stated by the Infectious Diseases Society of America 3

For HIV-infected or immunocompromised patients, the Centers for Disease Control and Prevention recommends using standard oral doses but extending duration to 7-14 days 1
The Infectious Diseases Society of America recommends not using short-course (1-3 day) therapy in HIV-infected patients 1

The American Academy of Dermatology recommends considering daily suppressive therapy for patients with ≥6 recurrences per year 3
The Infectious Diseases Society of America recommends valacyclovir 500mg once daily, famciclovir 250mg twice daily, or acyclovir 400mg twice daily for suppressive therapy 3

The Centers for Disease Control and Prevention recommends that dose adjustment is mandatory in patients with significant renal impairment to prevent acute renal failure 1, 4

The American Academy of Pediatrics recommends not relying on topical antivirals as primary therapy, as they are substantially less effective than oral agents and cannot reach sites of viral reactivation 5, 3, 4, 2
The Infectious Diseases Society of America recommends not using inadequate dosing, such as short-course, high-dose therapy, and not delaying treatment initiation, as waiting until lesions fully develop significantly reduces efficacy 3, 4

The Centers for Disease Control and Prevention recommends monitoring for common side effects, such as headache, nausea, and diarrhea, which are typically mild to moderate 3
The American Academy of Dermatology recommends no routine laboratory monitoring needed for episodic or suppressive therapy unless significant renal impairment exists 1